The impact of the revised ESC Dyslipidaemia Guidelines on lipid-lowering therapy: simulating the need for PCSK9 inhibition in a contemporary ASCVD cohort

28 August 2020 (08:00 - 18:00)

Organised by:

Abstract

Sign in to view the resources

Slides

About the speaker

Doctor Christopher Blaum

University Heart and Vascular Centre Hamburg (UHZ), Hamburg (Germany)

217 More presentations in this session

Presentation thumbnail

The association between napping and the risk of cardiovascular disease and all-cause mortality: a systematic review and dose-response meta-analysis

Doctor Z. Pan (Guangzhou, CN)

Abstract Slides

Presentation thumbnail

Prediction of 10-year and lifetime risk of cancer in individual patients with established cardiovascular disease, results from UCC-SMART and CANTOS

Miss C. van 't Klooster (Utrecht, NL)

Abstract Slides

Presentation thumbnail

Geographical profiles of cardiovascular risk and the risk factors in China: data from a nationwide population-based screening project

Assistant Professor C. Wu (Beijing, CN)

Abstract Slides

Presentation thumbnail

Associations between life-course frailty and later-life heart size and function in the 1946 NSHD British birth cohort-an epidemiological study

Mr C. Topriceanu (London, GB)

Abstract Slides

Presentation thumbnail

Lipoprotein(a) and cardiovascular disease: prediction, attributable risk fraction and estimating benefits from novel interventions

Doctor P. Welsh (Glasgow, GB)

Abstract Slides

Access the full session

Session thumbnail

Risk Factors and Prevention ePosters

The Event

ESC Congress 2020

28 August 2020 08:00 CET

You may be interested in

Webinar

Unmet needs in lipid management: treatment goals and how to achieve them

Webinar

Risk assessment and lipid management in primary prevention

Congress Presentation

Optimal medical therapy for primary prevention

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources